Newsroom | 62819 results
Sorted by: Latest
-
Beren Therapeutics Announces Six Presentations at the 2026 Ara Parseghian Medical Research Fund (APMRF) Conference
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Beren Therapeutics P.B.C., the parent company of Mandos LLC and a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, today announced that the company will present six posters at the 2026 Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann-Pick Type C Research, sponsored by the family of former Notre Dame head football coach Ara Parseghian, taking place May 30 through June 2 in Tucson, Arizona. The posters...
-
Mountain Valley MD Advances Quicksome™ Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides Including BPC-157
TORONTO--(BUSINESS WIRE)--Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTC: MVMDF) is pleased to report on the advancement of its patented Quicksome™ sublingual delivery platform as part of the Company’s strategy to position Quicksome™ as a differentiated delivery solution within the evolving compounded peptide marketplace across North and South America. Over the past six months, the Company has expanded its internal formulation capabilities following investments in l...
-
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)--BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in.......
-
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC). At seven years, patients treated with LORBRENA had a 55% likelihood of re...
-
Research Presented by The US Oncology Network Demonstrates How Community Practices Are Expanding Patient Access Through APP‑Led Models at ASCO 2026
THE WOODLANDS, Texas--(BUSINESS WIRE)--Research presented by The US Oncology Network found that new patient consult models led by advanced practice providers can accelerate access to care....
-
A New Perspective on the Universe, a Breakthrough in Medical Equity: Top Honours at the 2026 Canada-Wide Science Fair
EDMONTON, Alberta--(BUSINESS WIRE)--Youth Science Canada presented the top awards at the 2026 Canada-Wide Science Fair (CWSF) on Thursday evening in Edmonton, Alta....
-
Un nouveau regard sur l'univers, une percée pour l'équité en santé : les grands honneurs de l'Expo-sciences pancanadienne 2026
EDMONTON, Alberta--(BUSINESS WIRE)--Sciences jeunesse Canada a présenté les grands prix de l'Expo-sciences pancanadienne (ESPC) 2026 jeudi soir à Edmonton (Alb.), où 390 finalistes de partout au Canada ont présenté 344 projets et se sont disputé près de 2 millions de dollars en prix, dans le cadre du plus grand événement en STIM pour les jeunes au Canada. Faits saillants : Liam Desre, de Kingston (Ont.), a remporté le Prix du meilleur projet — Découverte pour avoir proposé un nouveau modèle de...
-
PanTher Completes Dose Escalation Phase in Non-Metastatic Pancreatic Cancer Phase 1b Trial and Appoints Tim Clackson to the Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining early cancer treatment with therapeutic implants administered directly at the tumor site, today announced that it has concluded the dose escalation portion of its Phase 1b clinical trial of PTM-101 in pancreatic ductal adenocarcinoma (PDAC). PanTher has identified the PTM-101 400mg paclitaxel-containing implant as the recommended Phase 2 dose (RP2D) in combination with neoadjuv...
-
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C-mutation and e...
-
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further suppo...
